No committee data
Expert AnalysisPro
/ 100 Political Alpha
Upgrade to see committee overlap, performance context, and full expert analysis.
Buy price
Return since trade
Follow $10K gain
Expert analysis is Pro-only
UpgradeLive
Track congressional trades for ALABALAB congressional trades
2 matched disclosures
Tracked disclosures
2
Lawmakers
1
Buy / sell
0 / 2
Avg post-trade move
N/A
Latest filing 2025-03-27
ALAB congressional trades snapshot
This page summarizes public STOCK Act disclosures involving ALAB. It is useful for seeing which lawmakers reported ALAB transactions, how many filings are visible, the buy/sell mix, and whether the newest public filing describes a recent or delayed trade.
Last updated
Mar 27, 2025
Data source
Public House and Senate STOCK Act disclosures normalized by Congressional Trader.
Key caveat
Filing date can trail transaction date. This page is for research and monitoring, not investment advice.
What the ALAB congressional trade page shows
Congressional Trader tracks 2 public STOCK Act disclosures for ALABacross 1 lawmakers. This page separates purchases from sales, shows filing delays, and links each disclosure back to the individual politician profile when available.
The most recent ALAB filing shown here was filed on Mar 27, 2025 by Robert P. Bresnahan as a sale. Related lawmakers include Robert P. Bresnahan.
Top lawmakers for ALAB
Pro performance summary
Unlock 30/90-day post-trade summaries, committee overlap, and CSV-oriented research views for high-intent ticker research.
Compare Pro plansNo committee data
Expert AnalysisPro
/ 100 Political Alpha
Upgrade to see committee overlap, performance context, and full expert analysis.
Buy price
Return since trade
Follow $10K gain
Expert analysis is Pro-only
UpgradeFAQ
Which lawmakers traded ALAB?
Recent ALAB disclosures include Robert P. Bresnahan.
What is the buy/sell mix for ALAB?
The visible sample currently shows 0 purchases and 2 sales or partial sales.
Should I trade based on ALAB disclosures?
No. This page summarizes public filings for research and monitoring. It is not investment advice.